Clinical Trial Update: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 open-label study evaluating ONO-7913 and ONO-4538 in combination with modified FOLFIRINOX as first-line therapy for metastatic pancreatic canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ONO-4538
• ONO-7913

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING